Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.53 |
| ▸ | CCND1 | P24385 | 20/20 | 0.53 |
| ▸ | CDK2 | P24941 | 8/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344001 | 0.94 | CDK4 (0.60) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6341299 | 0.93 | CDK4 (0.53) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7662345 | 0.88 | CDK4 (0.63) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6352506 | 0.88 | CDK4 (0.52) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6346628 | 0.88 | CDK4 (0.52) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6341289 | 0.87 | CDK4 (0.58) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6343079 | 0.86 | CDK4 (0.52) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6343063 | 0.84 | CDK4 (0.57) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6340767 | 0.83 | CDK4 (0.55) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7664909 | 0.82 | CDK4 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020091127-A1 | Semicarbazides and their uses | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-11 | — | — | US | claimed |
| US-6849631-B2 | Semicarbazides and their uses | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20020091127-A1 | Semicarbazides and their uses | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091127-A1 | Semicarbazides and their uses | CDK1, CCNA1, CDK17 | CDK4 12/4885CCND1 37/4885CDK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.